CARDIFF ONCOLOGY INC

Cardiff Oncology’s insider buying surge signals confidence amid a low‑price offering, highlighting potential upside for value‑seeking investors in the biotech sector.

Cardiff Oncology insider‑buying spurs investor curiosity: insider options, a 52‑week low, and a solid‑tumor ADC pipeline may signal upside if clinical milestones hit.